Should an adult patient with apical hypertrophic cardiomyopathy and apical aneurysm who has undergone ablation for atrial flutter and sustained ventricular tachycardia and has a cardiac resynchronization therapy‑defibrillator (CRT‑D) implanted receive the high‑dose influenza vaccine (Fluad), an RSV vaccine, and the recombinant herpes zoster vaccine (Shingrix)?

Vaccination Recommendations for Apical HCM Patient with CRT-D

Yes, this patient should receive all three vaccines: high-dose influenza vaccine (Fluad), RSV vaccine, and recombinant herpes zoster vaccine (Shingrix). This patient with severe cardiovascular disease and an implanted cardiac device has compelling indications for comprehensive vaccination to prevent infectious complications that could trigger life-threatening arrhythmias or heart failure decompensation.

Influenza Vaccination (Fluad)

The AHA/ACC strongly recommends annual influenza vaccination as Class I, Level B evidence for all patients with cardiovascular disease 1. This recommendation applies with the same emphasis as cholesterol and blood pressure control. Key considerations:

• Patients with CVD face higher risk of influenza-related death than those with any other chronic condition 1
• Influenza can precipitate acute cardiovascular events, arrhythmias, and heart failure exacerbations 1
• Use inactivated vaccine (intramuscular) only—live attenuated intranasal vaccine is contraindicated in cardiovascular patients 1
• High-dose formulations like Fluad are appropriate for enhanced immune response, particularly given this patient's complex cardiac status

The presence of a CRT-D device is not a contraindication; in fact, it underscores the need for prevention of any systemic illness that could destabilize cardiac rhythm or function.

RSV Vaccination

While the provided evidence doesn't specifically address RSV vaccination, this patient with severe structural heart disease and history of sustained ventricular tachycardia would benefit from RSV prevention. Respiratory viral infections can trigger:

• Acute heart failure decompensation
• Increased arrhythmia burden
• Cardiovascular events similar to influenza

Given the parallel risk profile to influenza and the availability of safe inactivated RSV vaccines, vaccination is appropriate for this high-risk cardiac patient.

Herpes Zoster Vaccination (Shingrix)

Shingrix is recommended and safe for this patient 2. Critical points:

• Shingrix is a recombinant (non-live) vaccine, making it safe for patients with cardiac devices and complex cardiovascular disease 2
• The vaccine is administered as two intramuscular doses, 2-6 months apart (standard schedule) 2
• The only contraindication is prior severe allergic reaction to vaccine components 2

Important safety considerations:

• Syncope can occur with any injectable vaccine—ensure patient is seated/lying down during administration with observation period 2
• Post-marketing data identified increased Guillain-Barré syndrome risk in the 42 days post-vaccination, though absolute risk remains low 2
• Common reactions include injection site pain (78%), myalgia (45%), and fatigue (45%), but these are self-limited 2

The CRT-D device itself poses no contraindication to vaccination. While the patient has undergone multiple ablations for atrial flutter and VT, these procedures don't create immunocompromise that would preclude vaccination.

Clinical Rationale

This patient's risk profile demands aggressive preventive measures:

1. Apical HCM with aneurysm creates substrate for malignant arrhythmias 3, 4
2. History of sustained VT indicates high arrhythmic risk despite ablation and CRT-D 3
3. Any systemic infection (influenza, RSV, herpes zoster) could:
   • Trigger VT storm requiring multiple ICD shocks
   • Precipitate heart failure
   • Increase metabolic demands on compromised myocardium
   • Lead to hospitalization with attendant risks

Practical Implementation

Administer vaccines on separate visits to distinguish any adverse reactions and avoid cumulative reactogenicity. Suggested sequence:

1. Influenza vaccine first (seasonal priority)
2. Shingrix dose 1 (2-4 weeks later)
3. RSV vaccine (2-4 weeks after Shingrix)
4. Shingrix dose 2 (2-6 months after dose 1)

Monitor for 15 minutes post-injection for syncope/allergic reactions. Counsel patient about expected local and systemic reactions, particularly with Shingrix, which has higher reactogenicity but excellent efficacy.

The cardiovascular benefits of preventing infectious complications far outweigh the minimal risks of these inactivated/recombinant vaccines in this high-risk patient.